1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted by our directors and executive officers during the quarter ended June 30, 2025.
−Removed: No trading arrangements were terminated by our directors and executive officers during the quarter ended June 30, 2025.
+Added: The following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted by our directors and executive officers during the quarter ended September 30, 2025.
+Added: No trading arrangements were terminated by our directors and executive officers during the quarter ended September 30, 2025.
Trading Arrangement
−Removed: Name and Position Action Date Rule 10b5-1* Non-Rule
+Added: Name and Position Action Date Rule
+Added: 10b5-1* Non-Rule
10b5-1** Total Number of
Shares to be Sold Expiration
−Removed: Abraham Ceesay
+Added: Jonathan Slonin
+Added: Chief Medical Officer
Adopt 8/12/2025 x 10,261 8/28/2026
−Removed: Chief Financial Officer
−Removed: Adopt 6/9/2025 x To Be Determined (1)
−Removed: Principal Accounting Officer
+Added: Kristen Williams
+Added: Chief Administrative Officer and Secretary
Adopt 9/10/2025 x To Be Determined (1)
1 unchanged sentence
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).
−Removed: (1) The aggregate number of shares to be sold pursuant to the trading arrangements listed above are dependent on the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time.
−Removed: (2) Includes shares to be sold which are scheduled to be purchased through the Company’s employee stock purchase plan on December 31, 2025.
+Added: (1) The aggregate number of shares to be sold pursuant to the trading arrangements listed above are dependent on, among other things, sale prices under the trading arrangements and the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time.
Pacira BioSciences, Inc.
−Removed: | Q2 2025 Form 10-Q | Page 58
+Added: | Q3 2025 Form 10-Q | 61
The exhibits listed below are filed or furnished as part of this report.
Exhibit Number Description
−Removed: Settlement Agreement, dated April 7, 2025, by and between Pacira BioSciences, Inc.
−Removed: and Pacira Pharmaceuticals, Inc.
−Removed: with Fresenius Kabi USA, LLC, eVenus Pharmaceutical Laboratories Inc., and Jiangsu Hengrui Pharmaceuticals Co., Ltd.
−Removed: (f/k/a Jiangsu Hengrui Medicine Co., Ltd.).(1) †† ##
−Removed: Amended and Restated 2011 Stock Incentive Plan.(2)***
+Added: Credit Agreement, dated as of July 3, 2025, by and among Pacira BioSciences, Inc., the lenders from time to time party thereto and Wells Fargo Bank, National Association, as administrative agent, swingline lender and an issuing bank.(1) ##
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
3 unchanged sentences
101 The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc.
−Removed: for the quarter ended June 30, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: for the quarter ended September 30, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) the Condensed Consolidated Balance Sheets;
(ii) the Condensed Consolidated Statements of Operations;
−Removed: (iii) the Condensed Consolidated Statements of Comprehensive (Loss) Income;
+Added: (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss);
(iv) the Condensed Consolidated Statements of Stockholders’ Equity;
5 unchanged sentences
*** Denotes management contract or compensatory plan or arrangement.
−Removed: Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K.
−Removed: The omitted information (i) is not material and (ii) is the type that the Registrant treats as private or confidential.
−Removed: (1) Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q, filed on May 8, 2025.
−Removed: (2) Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on June 13, 2025.
+Added: ## Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
+Added: The Company hereby undertakes to supplementally furnish copies of any omitted schedules and exhibits to the Securities and Exchange Commission upon request.
+Added: (1) Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on July 7, 2025.
Pacira BioSciences, Inc.
−Removed: | Q2 2025 Form 10-Q | Page 59
+Added: | Q3 2025 Form 10-Q | 62
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PACIRA BIOSCIENCES, INC.
−Removed: August 5, 2025 By:
+Added: November 6, 2025 By:
Chief Executive Officer and Director
(Principal Executive Officer)
−Removed: August 5, 2025 By:
+Added: November 6, 2025 By:
Chief Financial Officer
1 unchanged sentence
Pacira BioSciences, Inc.
−Removed: | Q2 2025 Form 10-Q | Page 60
+Added: | Q3 2025 Form 10-Q | 63
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.